Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 38.0%

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 36,300 shares, a growth of 38.0% from the February 13th total of 26,300 shares. Based on an average daily volume of 98,300 shares, the short-interest ratio is presently 0.4 days. Currently, 1.9% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new position in Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent quarter. Institutional investors own 1.16% of the company’s stock.

Tharimmune Stock Performance

Tharimmune stock traded up $0.02 during trading hours on Tuesday, reaching $1.43. The stock had a trading volume of 426 shares, compared to its average volume of 348,716. The business’s 50 day moving average price is $1.83 and its 200-day moving average price is $2.18. Tharimmune has a 52 week low of $1.28 and a 52 week high of $7.46.

Analyst Ratings Changes

Several equities analysts recently issued reports on THAR shares. Rodman & Renshaw started coverage on shares of Tharimmune in a report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective on the stock. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).